Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 04, 2019 02:00 ET | Source: Motif Bio plc

Motif Bio to Present Iclaprim Data at ECCMID 2019

NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that four...
March 20, 2019 03:00 ET | Source: Motif Bio plc

Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim

NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the U.S....
March 18, 2019 03:00 ET | Source: Motif Bio plc

Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board

NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Richard...
February 19, 2019 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio Conference Call and Webcast

NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the...
February 18, 2019 02:00 ET | Source: Motif BioSciences Inc.

Motif BioSciences Enters into Amendment Agreement with Hercules Capital

NEW YORK, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Motif...
February 14, 2019 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio Receives Complete Response Letter from the FDA

NEW YORK, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the...
October 31, 2018 03:00 ET | Source: Motif BioSciences Inc.

Motif Bio to participate at upcoming Jefferies London Healthcare Conference

NEW YORK, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the...
October 03, 2018 03:01 ET | Source: Motif BioSciences Inc.

Motif Bio Presents New Iclaprim Data at IDWeek

Iclaprim safety and efficacy in patients with wound infections in REVIVE Phase 3 trials NEW YORK, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage...
September 25, 2018 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress

NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD...
September 20, 2018 02:00 ET | Source: Motif BioSciences Inc.

Motif Bio to Present Iclaprim Data at Upcoming Scientific Conferences

NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim...